Navigation Links
Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:9/29/2011

SAN DIEGO, Sept. 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society. This meeting will be held October 1-5, 2011 in Orlando, FL at the Orlando World Center Marriott.

Details on the presentation times are as follows:Monday, October 3, 2011 – Abstract #598-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Robert Chilton, DO; University of Texas Health Science Center, San Antonio, TX, USA.Title: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart FailureMonday, October 3, 2011 – Abstract #605-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Ken Fujioka, MD; Scripps Clinic, La Jolla, CA, USA.Title: Completion of 56 Weeks of Naltrexone SR/Bupropion SR Combination Therapy Increases Likelihood of Achieving Improvements in Markers of Cardiometabolic Risk Associated with Clinically Meaningful Weight LossMonday, October 3, 2011 – Abstract #607-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Patrick O'Neil, PhD; Medical University of South Carolina, Charleston, SC, USA.Title: Naltrexone SR/Bupropion SR and Intensive Behavioral Modification Combination Increases the Likelihood of Achieving Early and Sustained Weight Loss and Associated Improvement in Markers of Cardiometabolic RiskMonday, October 3, 2011 – Abstract #49-OR, Presentation time 3:15-4:45PM EDT, "Intervention and Clinical Studies - Surgery/Drugs" SessionPresenter: Gene-Jack Wang, MD; Brookhaven National Laboratory, Upton, NY Title: Reduced responses to food cue after combined therapy
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
2. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
3. Orexigen® Therapeutics Announces Corporate Realignment
4. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
7. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
8. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
9. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
10. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
11. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Kamal Rashid , PhD, ... and Training Center (BETC) and research professor of biology ... 2014 , an international two-day event focused on biomanufacturing ... Global Summits, the event will bring together leaders of ... to develop and produce human therapeutics. “The growth curve ...
(Date:9/23/2014)... VA (PRWEB) September 23, 2014 ATCC, ... is pleased to announce two important appointments to the ... Executive Vice President of Strategy and Technology and Dr. ... for the Standards Resource Center. Both roles are new ... H. Cypess, President and CEO at ATCC described the ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
(Date:9/23/2014)... 23, 2014   GenoSpace , a precision medicine ... tools to enable the broad use of genomic data ... has been awarded Phase I of a Fast Track ... Institutes of Health (NIH) to enable enhanced data access ... http://photos.prnewswire.com/prnh/20140922/147649 During the past ...
Breaking Biology Technology:Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... BOCA RATON, Fla., Oct. 30 Nabi,Biopharmaceuticals (Nasdaq: ... Group (ISS) and Glass Lewis & Co., two ... that stockholders of the,Company vote "FOR" the Company,s ... certain Corporate Shared Services assets to Biotest,Pharmaceuticals Corporation, ...
... (OTC,Bulletin Board: NNLX) a nano-biotechnology company announces the date ... meeting will take place at 1 PM on 12/28/07 ... A call-in number will be provided for,questions to management. ... days prior to the meeting. Shareholders of record as ...
... 30 /PRNewswire-FirstCall/ - ICBS Limited,(PINKSHEETS: ICBM), today announced ... Bacteria Bank Ltd., is a Bio medical ... for use in medical research, located,in Montreal Canada. ... a world,renowned bacteriologist. Dr. Karl Weiss is ...
Cached Biology Technology:RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 2RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 3NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 2NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 3ICBS acquires 30% interest in Bacteria Bank Ltd. 2
(Date:9/23/2014)... body forms new tissues during the healing process, ... other. For years, scientists believed this communication happened ... Mellon University and the University of Pittsburgh have ... is equally if not more crucial. The findings, ... Proceedings of the National Academy of Sciences , ...
(Date:9/23/2014)... Research by Rice University scientists who are fighting a ... be a clinician,s most powerful ally. , "Recent research ... cyberwarfare against the immune system, and we studied the ... how we might turn the tables on cancer," said ... this week in the Early Edition of the ...
(Date:9/23/2014)... identified a gene mutation that causes aplastic anemia, ... marrow fails to produce normal amounts of blood ... had blood disorders, the researchers discovered a defect ... with crucial roles in normal cell function. , ... molecular-based treatments that bypass the gene defect and ...
Breaking Biology News(10 mins):The mechanics of tissue growth 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3Gene mutation discovered in blood disorder 2
... Holy Grails of nanotechnology, but nature has been producing ... scientists has taken a unique look at how thousands ... clusters that direct cell movement to select chemicals in ... complex periodic patterns in biological systems can be generated ...
... Alexopoulos Prize will be given to Dr. Brian Shaw, Texas ... 29 in Snowbird, Utah. The honor based on ... known as the Outstanding Early-Career Mycologist Award of the Mycological ... and four review papers in 12 years. Both the National ...
... This release is available in Spanish . ... technique consisting of the induction of neuronal degeneration neuronal for ... helpful for the study of retinitis pigmentosa (RP), a group ... than one million persons a year all over the world. ...
Cached Biology News:Spontaneous assembly 2Spontaneous assembly 3Spontaneous assembly 4Work in mice will contribute to the study of hereditary diseases that lead to blindness 2
...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
PP2B-Abeta (C-20)...
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
Biology Products: